Eloxx Pharmaceuticals, Inc.

ARLINGTON, Mass., Nov. 2, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that Sumit Aggarwal, President and Chief Executive Officer, will present at the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9–11, 2026.

FDA clearance of the IND enables Eloxx to open U.S. clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKD EXPRESS will randomize approximately 60 patients 1:1 to exaluren or placebo for 52 weeks, with annualized htTKV growth as the primary endpoint; first patient dosing expected in 3Q 2027 and topline data in 1H 2029 FDA pre-IND feedback indicated that a substantial and durable htTKV effect could support Breakthrough Therapy Designation; FDA also lists htTKV…

EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to ex aluren or placebo, with annualized htTKV growth as the primary endpoint Substantial, durable htTKV effect could support Breakthrough Therapy Designation; FDA also lists htTKV as a potential surrogate endpoint for accelerated approval in ADPKD First patient dosing expected in 3Q 2027, and 52-week topline data expected in 1H 2029 Orphan drug designation granted for ADPKD in the US in addition to …

Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business Extensive public company board experience, including current service as Chairman of Entera Bio and as a director of Precision BioSciences ARLINGTON, Mass., Oct. 19, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases,…

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) and Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends. Profitability This table compares LENZ Therapeutics and

First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027 ARLINGTON, Mass., Sept. 11, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial evaluating e…

Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026 European Commission granted orphan designation for exaluren in ADPKD Cash and cash equivalents of $62.0 million as of June 30, 2026, expected to fund operations through data readouts for both Alport sy…